Efficacy and Safety of Lenalidomide, PD-1 Monoclonal Antibodies Combined with Orelabrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase II Study

被引：0
|
作者：
Wang, Lingling [1 ]
Huang, Yongfen [1 ]
Chen, Hui [1 ]
Xu, Hao [1 ]
Cheng, Yuexin [1 ]
Miao, Yuqing [1 ]
机构：
[1] Xuzhou Med Univ, Peoples Hosp Yancheng 1, Yancheng Clin Coll, Dept Hematol, Yancheng, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198309
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6488 / 6489
页数：2
相关论文
共 50 条
  • [41] Everolimus (EVE) for relapsed/refractory classical Hodgkin lymphoma (cHL): Open-label, single-arm, phase II study.
    Johnston, Patrick B.
    Pinter-Brown, Lauren C.
    Rogerio, Jaqueline Willemann
    Warsi, Ghulam
    Chau, Quincy
    Ramchandren, Rod
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] An open label, single arm, multicenter phase II study of the efficacy and safety of LP-168 monotherapy for relapsed or refractory mantle cell lymphoma.
    Song, Yuqin
    Tang, Xiaoqiong
    Cai, Qingqing
    Liu, Lihong
    Jing, Hongmei
    Jiang, Ming
    Sun, Xiuhua
    Wu, Jianqiu
    Yang, Yu
    Wu, Huijing
    Peng, Zhigang
    Ding, Kaiyang
    Yi, Shuhua
    Yan, Xiaojing
    Wu, Guowu
    Wu, Yudan
    Cui, Jie
    Ou, Pengju
    Tan, Fenlai
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] The efficacy and safety of Geptanolimab (GB226) in patients with relapsed/refractory peripheral T cell lymphoma (PTCL): A multicenter, open-label, single-arm, phase 2 trial
    Shi, Yuankai
    Wu, Jianqiu
    Wang, Zhen
    Zhang, Liling
    Wang, Zhao
    Zhang, Mingzhi
    Cen, Hong
    Peng, Zhigang
    Li, Yufu
    Fan, Lei
    Guo, Ye
    Ma, Liping
    Cui, Jie
    Gao, Yuhuan
    Yang, Haiyan
    Zhang, Hongyu
    Wang, Lin
    Zhang, Weihua
    Zhang, Huilai
    Xie, Liping
    Jiang, Ming
    Zhou, Hui
    Shuang, Yuerong
    Su, Hang
    Ke, Xiaoyan
    Jin, Chuan
    Du, Xin
    Du, Xin
    Liu, Li
    Xi, Yaming
    Ge, Zheng
    Feng, Ru
    Zhang, Yang
    Zhou, Shengyu
    Xie, Fan
    Gao, Chao
    CANCER RESEARCH, 2020, 80 (16)
  • [44] Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma
    Suzuki, Kenshi
    Sunami, Kazutaka
    Matsumoto, Morio
    Maki, Akio
    Shimada, Fumika
    Suzuki, Kazuyuki
    Shimizu, Kazuyuki
    ACTA HAEMATOLOGICA, 2021, 144 (03) : 264 - 274
  • [45] A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Wang, Jie
    Asch, Adam S.
    Hamad, Nada
    Weickhardt, Andrew
    Tomaszewska-Kiecana, Monika
    Dlugosz-Danecka, Monika
    Pylypenko, Halyna
    Bahadur, Shakeela
    Ulahannan, Susanna
    Koucheki, Janine
    Sun, Jichao
    Li, Hua
    Chen, Francine
    Zhang, Xiaoyu
    Muth, John
    Kaminker, Patrick
    Moore, Paul
    Sumrow, Bradley James
    BLOOD, 2020, 136
  • [46] L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL)-A SINGLE-ARM PHASE II STUDY
    Maddocks, K.
    Gonzalez Barca, E.
    Jurczak, W.
    Liberati, A. M.
    Duell, J.
    Nagy, Z.
    Papaj-K, T.
    Andre, M.
    Kalakonda, N.
    Dreyling, M.
    Zinzani, P. L.
    Ambarkhane, S.
    Weirather, J.
    Salles, G.
    HAEMATOLOGICA, 2017, 102 : 174 - 174
  • [47] L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study
    Duell, J.
    Gonzalez Barca, E.
    Liberati, A. M.
    Salles, G.
    Gaidano, G.
    Jurczak, W.
    Nagy, Z.
    Papajlk, T.
    Andre, M.
    Zinzani, P. L.
    Kalakonda, N.
    Ambarkhane, S.
    Weirather, J.
    Maddocks, K.
    Dreyling, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 68 - 68
  • [48] A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Cassaday, Ryan D.
    Goy, Andre
    Advani, Suresh
    Chawla, Purvi
    Nachankar, Rajesh
    Gandhi, Mansi
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (07): : 392 - 397
  • [49] Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
    Mei, Qian
    Zhang, Wenying
    Liu, Yang
    Yang, Qingming
    Rasko, John E. J.
    Nie, Jing
    Liu, Jiejie
    Li, Xiang
    Dong, Liang
    Chen, Meixia
    Zhang, Yan
    Shi, Lu
    Wu, Huitao
    Han, Weidong
    CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4521 - 4530
  • [50] Single Agent Ofatumumab In Patients With Relapsed and/Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results From a Phase II Open Label Study
    Jasielec, Jagoda
    Peace, David
    Edwards, Sarah
    Tolzien, Kathy
    Smith, Sonali M.
    Nabhan, Chadi
    BLOOD, 2013, 122 (21)
12345